Search

Your search keyword '"Mata Romero, Pilar"' showing total 13 results
Start Over Author "Mata Romero, Pilar"
13 results on '"Mata Romero, Pilar"'

3. New entity of adult ultra-short coeliac disease: the first international cohort and case–control study

Author

Raju, Suneil A, primary, Greenaway, Emily A, additional, Schiepatti, Annalisa, additional, Arpa, Giovanni, additional, Vecchione, Nicoletta, additional, Jian, Chao LA, additional, Grobler, Charlotte, additional, Maregatti, Margherita, additional, Green, Olivia, additional, Bowker-Howell, Freya J, additional, Shiha, Mohamed G, additional, Penny, Hugo A, additional, Cross, Simon S, additional, Ciacci, Carolina, additional, Rostami, Kamran, additional, Ahmadipour, Shokoufeh, additional, Moradi, Afshin, additional, Rostami-Nejad, Mohammad, additional, Biagi, Federico, additional, Volta, Umberto, additional, Fiorentino, Michelangelo, additional, Lebwohl, Benjamin, additional, Green, Peter HR, additional, Lewis, Suzanne, additional, Molina-Infante, Javier, additional, Mata-Romero, Pilar, additional, Vaira, Valentina, additional, Elli, Luca, additional, Soykan, Irfan, additional, Ensari, Arzu, additional, and Sanders, David S, additional

Published
2024
Full Text
View/download PDF

4. Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on Helicobacter pylori Management (Hp-EuReg).

Author

Pérez-Aisa, Ángeles, Nyssen, Olga P., Keco-Huerga, Alma, Rodrigo, Luís, Lucendo, Alfredo J., Gomez-Rodriguez, Blas J., Ortuño, Juan, Perona, Mónica, María Huguet, José, Núñez, Oscar, Fernandez-Salazar, Luis, Barrio, Jesus, Lanas, Angel, Iyo, Eduardo, Mata Romero, Pilar, Fernández-Bermejo, Miguel, Gomez, Barbara, Garre, Ana, Gomez-Camarero, Judith, and Lamuela, Luis Javier

Subjects
HELICOBACTER pylori infections, HELICOBACTER pylori, DUODENAL ulcers, SCHEDULING, BISMUTH, DRUG resistance in bacteria
Published
2023
Full Text
View/download PDF

5. Helicobacter pylori Diagnostic Tests Used in Europe: Results of over 34,000 Patients from the European Registry on Helicobacter pylori Management.

Author

García-Morales, Natalia, Pérez-Aísa, Ángeles, Fiorini, Giulia, Tepes, Bojan, Castro-Fernández, Manuel, Lucendo, Alfredo, Voynovan, Irina, Bujanda, Luis, Garre, Ana, Rodrigo, Luis, Martínez Domínguez, Samuel Jesús, Denkovski, Maja, Huguet Malavés, Jose M., Jonaitis, Laimas, Bumane, Renate, Zaytsev, Oleg, Mata Romero, Pilar, Barrio, Jesús, Fernández-Salazar, Luis, and Sarsenbaeva, Aiman Silkanovna

Subjects
HELICOBACTER pylori, DIAGNOSIS methods, HELICOBACTER pylori infections, BREATH tests
Abstract

Background and aims: Several methods are available to diagnose Helicobacter pylori infection. Our objective was to evaluate the tests used for both the initial diagnosis and the confirmation of eradication after treatment in Europe. Methods: The European Registry on the management of Helicobacter pylori infection is an international, multicentre, prospective, non-interventional registry aiming to evaluate the management of Helicobacter pylori-infected patients in Europe. Countries with at least 100 cases registered from June 2013 to April 2021, and with a validated diagnostic method were analysed. Data were quality reviewed. Results: A total of 34,920 adult patients from 20 countries were included (mean age 51 years; 61% women). To establish the initial diagnosis, invasive tests were performed in 19,801 (71%) patients, non-invasive in 11,369 (41%), and both in 3437 (12%). The most frequent were histology (n = 11,885; 43%), a rapid urease test (n = 10,636; 38%) and an urea breath test (n = 7577; 27%). According to the age, invasive tests were indicated in 11,179 (77%) ≥50 years, and in 8603 (65%) <50 years. Depending on the country, the use of invasive tests ranged from 29–99% in <50 years to 60–99% in ≥50. Most of the tests used to confirm eradication were non-invasive (n = 32,540; 93%), with the urea breath test being the most frequent (n = 32,540; 78%). In 2983 (9%) post-treatment tests, histology (n = 1887; 5%) or a rapid urease test (n = 1223; 4%) were performed. Conclusion: A great heterogeneity was observed for the initial diagnosis and confirmation of the eradication. The reasons for the apparent lack of adherence to the clinical guidelines should be further explored. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

6. Endoscopic ultrasound-guided fine-needle biopsy in patients with unexplained diffuse gastrointestinal wall thickening

Author

Chavarría, Carlos, additional, García-Alonso, Francisco J., additional, de Benito-Sanz, Marina, additional, Mata-Romero, Pilar, additional, Madrigal, Beatriz, additional, Sanchez-Ocaña, Ramon, additional, Diez-Redondo, Pilar, additional, Núñez, Henar, additional, Perez-Miranda, Manuel, additional, and de la Serna-Higuera, Carlos, additional

Published
2021
Full Text
View/download PDF

7. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Author

Caldas, Maria, Perez-Aisa, Angeles, Castro-Fernandez, Manuel, Bujanda, Luis, Lucendo, Alfredo J., Rodrigo, Luis, Huguet, Jose M., Perez-Lasala, Jorge, Molina-Infante, Javier, Barrio, Jesus, Fernandez-Salazar, Luis, Lanas, Angel, Perona, Monica, Dominguez-Cajal, Manuel, Ortuno, Juan, Gomez-Rodriguez, Blas Jose, Almela, Pedro, Botargues, Josep Maria, Nunez, Oscar, Modolell, Ines, Gomez, Judith, Ruiz-Zorrilla, Rafael, De la Coba, Cristobal, Huerta, Alain, Iyo, Eduardo, Pozzati, Liliana, Anton, Rosario, Barenys, Merce, Angueira, Teresa, Fernandez-Bermejo, Miguel, Campillo, Ana, Alcedo, Javier, Pajares-Villaroya, Ramon, Mego, Marianela, Bermejo, Fernando, Dominguez-Jimenez, Jose Luis, Tito, Llucia, Fernandez, Nuria, Pabon-Carrasco, Manuel, Cosme, Angel, Mata-Romero, Pilar, Alcaide, Noelia, Arino, Ines, Di Maira, Tommaso, Garre, Ana, Puig, Ignasi, Nyssen, Olga P., Megraud, Francis, O'Morain, Colm, Gisbert, Javier P., Hp EuReg Investigators, and UAM. Departamento de Medicina

Subjects
Microbiology (medical), second-line, Helicobacter pylori infection, medicine.medical_specialty, Multivariate analysis, Medicina, Therapeutics, Biochemistry, Microbiology, 03 medical and health sciences, 0302 clinical medicine, Antibiotic resistance, Moxifloxacin, Internal medicine, Medicine, Pharmacology (medical), General Pharmacology, Toxicology and Pharmaceutics, Medical prescription, first-line, Helicobacter pylori, Spain, first-line, second-line, treatment, Second line treatment, biology, Helicobacter pylori, treatment, business.industry, lcsh:RM1-950, Infeccions per Helicobacter pylori, biology.organism_classification, Terapèutica, Helicobacter pylori infections, bacterial infections and mycoses, Infectious Diseases, lcsh:Therapeutics. Pharmacology, Spain, 030220 oncology & carcinogenesis, Concomitant, 030211 gastroenterology & hepatology, business, medicine.drug
Abstract

The management of Helicobacter pylori infection has to rely on previous local effectiveness due to the geographical variability of antibiotic resistance. The aim of this study was to evaluate the effectiveness of first and second-line H. pylori treatment in Spain, where the empirical prescription is recommended. A multicentre prospective non-interventional registry of the clinical practice of European gastroenterologists concerning H. pylori infection (Hp-EuReg) was developed, including patients from 2013 until June 2019. Effectiveness was evaluated descriptively and through a multivariate analysis concerning age, gender, presence of ulcer, proton-pump inhibitor (PPI) dose, therapy duration and compliance. Overall, 53 Spanish hospitals were included, and 10,267 patients received a first-line therapy. The best results were obtained with the 10-day bismuth single-capsule therapy (95% cure rate by intention-to-treat) and with both the 14-day bismuth-clarithromycin quadruple (PPI-bismuth-clarithromycin-amoxicillin, 91%) and the 14-day non-bismuth quadruple concomitant (PPI-clarithromycin-amoxicillin-metronidazole, 92%) therapies. Second-line therapies were prescribed to 2448 patients, with most-effective therapies being the triple quinolone (PPI-amoxicillin-levofloxacin/moxifloxacin) and the bismuth-levofloxacin quadruple schemes (PPI-bismuth-levofloxacin-amoxicillin) prescribed for 14 days (92%, 89% and 90% effectiveness, respectively), and the bismuth single-capsule (10 days, 88.5%). Compliance, longer duration and higher acid inhibition were associated with higher effectiveness. &ldquo, Optimized&rdquo, H. pylori therapies achieve over 90% success in Spain.

Published
2021

8. European Registry on Helicobacter pylori Management: Effectiveness of First and Second-Line Treatment in Spain

Author

Caldas, María, primary, Pérez-Aisa, Ángeles, additional, Castro-Fernández, Manuel, additional, Bujanda, Luis, additional, Lucendo, Alfredo, additional, Rodrigo, Luis, additional, Huguet, Jose, additional, Pérez-Lasala, Jorge, additional, Molina-Infante, Javier, additional, Barrio, Jesús, additional, Fernández-Salazar, Luis, additional, Lanas, Ángel, additional, Perona, Mónica, additional, Domínguez-Cajal, Manuel, additional, Ortuño, Juan, additional, Gómez-Rodríguez, Blas, additional, Almela, Pedro, additional, Botargués, Josep, additional, Núñez, Óscar, additional, Modolell, Inés, additional, Gómez, Judith, additional, Ruiz-Zorrilla, Rafael, additional, De la Coba, Cristóbal, additional, Huerta, Alain, additional, Iyo, Eduardo, additional, Pozzati, Liliana, additional, Antón, Rosario, additional, Barenys, Mercé, additional, Angueira, Teresa, additional, Fernández-Bermejo, Miguel, additional, Campillo, Ana, additional, Alcedo, Javier, additional, Pajares-Villaroya, Ramón, additional, Mego, Marianela, additional, Bermejo, Fernando, additional, Dominguez-Jiménez, José, additional, Titó, Llúcia, additional, Fernández, Nuria, additional, Pabón-Carrasco, Manuel, additional, Cosme, Ángel, additional, Mata-Romero, Pilar, additional, Alcaide, Noelia, additional, Ariño, Inés, additional, Di Maira, Tommaso, additional, Garre, Ana, additional, Puig, Ignasi, additional, Nyssen, Olga, additional, Megraud, Francis, additional, O’Morain, Colm, additional, and Gisbert, Javier, additional

Published
2020
Full Text
View/download PDF

9. Bismuth quadruple regimen with tetracycline or doxycycline versus three‐in‐one single capsule as third‐line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp‐EuReg)

Author

Nyssen, Olga P., primary, Perez‐Aisa, Angeles, additional, Rodrigo, Luis, additional, Castro, Manuel, additional, Mata Romero, Pilar, additional, Ortuño, Juan, additional, Barrio, Jesus, additional, Huguet, Jose Maria, additional, Modollel, Ines, additional, Alcaide, Noelia, additional, Lucendo, Alfredo, additional, Calvet, Xavier, additional, Perona, Monica, additional, Gomez, Barbara, additional, Gomez Rodriguez, Blas Jose, additional, Varela, Pilar, additional, Jimenez‐Moreno, Manuel, additional, Dominguez‐Cajal, Manuel, additional, Pozzati, Liliana, additional, Burgos‐Santamaria, Diego, additional, Bujanda, Luis, additional, Hinojosa, Jenifer, additional, Molina‐Infante, Javier, additional, Di Maira, Tommaso, additional, Ferrer, Luis, additional, Fernández‐Salazar, Luis, additional, Figuerola, Ariadna, additional, Tito, Llucia, additional, Coba, Cristobal, additional, Gomez‐Camarero, Judith, additional, Fernandez, Nuria, additional, Caldas, Maria, additional, Garre, Ana, additional, Resina, Elena, additional, Puig, Ignasi, additional, O’Morain, Colm, additional, Megraud, Francis, additional, and Gisbert, Javier P., additional

Published
2020
Full Text
View/download PDF

13. Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007–2016)

Author

Molina-Infante, Javier, Gonzalez-Cordero, Pedro Luis, Ferreira-Nossa, Hal Cliff, Mata-Romero, Pilar, Lucendo, Alfredo J., and Arias, Angel

Abstract

Epidemiologic studies on eosinophilic esophagitis (EoE) are scarce and patient responders to proton pump inhibitor (PPI) therapy have usually been excluded. We aimed to evaluate population-based incidence rates, prevalence and trends in adult EoE over the past decade, including responders to PPI therapy. We conducted an analysis of a prospectively established case registry in the health area of Cáceres, located in midwestern Spain. From the first EoE case diagnosed in 2007, endoscopy and pathology reports up to December 2016 were manually reviewed. A baseline diagnosis of EoE was confirmed upon symptoms of esophageal dysfunction (dysphagia/food impaction) and esophageal eosinophilia?=?15 eos/HPF. All patients were re-evaluated on PPI therapy during follow-up. A total of 137 patients were diagnosed with EoE during the study period, of whom 63 (46%) achieved clinicohistologic remission on PPI therapy. The prevalence of autoimmune disorders was low. Mean incidence rate was 8.09 new cases/100,000 inhabitants/year, increasing to 9.95 during the last lustrum and peaking in 2016 with 13.7. This trend coincided with late declining of esophageal biopsies rate. Overall prevalence in 2016 was 81.73 patients/100,000 inhabitants, with the highest prevalence in males between age 35 and 44 years (273 cases/100,000). No seasonal variation was observed in the diagnosis of EoE (53% during pollen season vs. 47%, p= 0.4). In midwestern Spain, incidence (13.7 cases/100,000 inhabitants/year) and prevalence (81.73 patients/100,000 inhabitants) in 2016 have grown remarkably in just one decade, coming closer to those figures recently reported for Crohn’s disease in Spain.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results